Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

February 10, 2025
By Daniel Morgensztern, MD
Mary Ellen Flanagan, NP
  • Janelle Mann, PharmD, BCOP

Commentary
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

In the first edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about best practices for implementing recently approved bispecific antibodies into cancer care. Their initial discussion focused on the clinical trial results, administration protocols, and toxicity management strategies related to the use of amivantamab-vmjw (Rybrevant) for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Morgensztern is a professor of Medicine and clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University in St. Louis. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine in St. Louis and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital.

Morgensztern began by giving an overview of amivantamab’s mechanism of action and highlighting supporting data for the agent when administered alone or in combination with other agents.

The FDA initially approved amivantamab monotherapy for patients with EGFR exon 20 insertion–mutant NSCLC in May 2021 based on data from the phase 1 CHRYSALIS trial (NCT02609776).1 Furthermore, the agency approved amivantamab/chemotherapy as frontline treatment for patients with NSCLC harboring EGFR exon 20 insertion mutations in March 2024 based on data from the phase 3 PAPILLON trial (NCT04538664).2 Findings from the phase 3 MARIPOSA trial (NCT04487080) also supported the FDA approval of amivantamab plus lazertinib (Lazcluze) for those with EGFR-mutant NSCLC in August 2024.3

Additionally, Mann reviewed key dosing considerations as patients receive amivantamab via intravenous infusion. She detailed the use of premedication such as diphenhydramine (Benadryl) to supplement amivantamab while monitoring for toxicities during the initial infusion period, which may necessitate additional dosing adjustments. Flanagan added to the conversation surrounding infusion-related reactions by describing strategies for mitigating the risk of venous thromboembolism, cutaneous toxicities, and other adverse effects.

References

  1. RYBREVANTTM (amivantamab-vmjw) receives FDA approval as the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. May 21, 2021. Accessed January 29, 2025. https://tinyurl.com/3d8wtu4m
  2. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. News release. FDA. March 1, 2024. Accessed January 29, 2025. https://tinyurl.com/msw4u5yk
  3. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed January 29, 2025. https://tinyurl.com/yxc8u8t4
Recent Videos
4 experts in this video
4 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Advertisement

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies

Tim Cortese
June 25th 2025
Article

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Russ Conroy
June 24th 2025
Article

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

Russ Conroy
June 20th 2025
Article

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.


Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

FDA Approves Taletrectinib in ROS1+ NSCLC

Ariana Pelosci
June 11th 2025
Article

Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

Related Content
Advertisement

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies

Tim Cortese
June 25th 2025
Article

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Russ Conroy
June 24th 2025
Article

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

Russ Conroy
June 20th 2025
Article

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.


Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

FDA Approves Taletrectinib in ROS1+ NSCLC

Ariana Pelosci
June 11th 2025
Article

Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.